Regeneron presents positive data from PANORAMA trial

Patients in the PANORAMA trial who underwent early intervention with Eylea experienced improvements in diabetic retinopathy severity, and the majority experienced prevention of serious vision-threatening complications.

Trial investigator Charles C. Wykoff, MD, PhD, presented the 1-year results of the phase 3 trial at Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration 2019 symposium in Miami. The double-masked, randomized trial included patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) treated with Eylea (aflibercept, Regeneron) every 16 weeks (135 participants) or every 8 weeks (134 participants) or with a sham control (133 participants).

“PANORAMA adds significantly to our understanding of how to manage NPDR without DME, as it is the first prospective trial involving high-risk NPDR eyes with moderately severe to severe NPDR since the landmark ETDRS trial of the 1980s, before we had pharmacologic treatments for DME,” Wykoff told Healio.com/OSN.

In a related press release, Regeneron reported that 74% of patients with severe NPDR who were treated with Eylea did not develop vision-threatening events at 1 year, whereas 53% of untreated patients did.

“Improvements in diabetic retinopathy severity achieved with aflibercept loading doses were maintained through 1 year with every 16-week re-treatments, a management approach that could realistically be achieved in the real world,” Wykoff said. – by Robert Linnehan

Disclosure: Wykoff reports he is a consultant for Alimera Sciences, Allegro, Allergan, Alnylam, Apellis, Bayer, Clearside Biomedical, DORC, EyePoint, Genentech/Roche, Kodiak, Notal Vision, Novartis, ONL Therapeutics, PolyPhotonix, Recens Medical, Regeneron, Regenxbio and Santen; is a researcher for Allergan, Apellis, Clearside Biomedical, EyePoint, Genentech/Roche, Neurotech, Novartis, Opthea, Regeneron, Regenxbio, Samsung and Santen; and is a speaker for Regeneron.

Patients in the PANORAMA trial who underwent early intervention with Eylea experienced improvements in diabetic retinopathy severity, and the majority experienced prevention of serious vision-threatening complications.

Trial investigator Charles C. Wykoff, MD, PhD, presented the 1-year results of the phase 3 trial at Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration 2019 symposium in Miami. The double-masked, randomized trial included patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) treated with Eylea (aflibercept, Regeneron) every 16 weeks (135 participants) or every 8 weeks (134 participants) or with a sham control (133 participants).

“PANORAMA adds significantly to our understanding of how to manage NPDR without DME, as it is the first prospective trial involving high-risk NPDR eyes with moderately severe to severe NPDR since the landmark ETDRS trial of the 1980s, before we had pharmacologic treatments for DME,” Wykoff told Healio.com/OSN.

In a related press release, Regeneron reported that 74% of patients with severe NPDR who were treated with Eylea did not develop vision-threatening events at 1 year, whereas 53% of untreated patients did.

“Improvements in diabetic retinopathy severity achieved with aflibercept loading doses were maintained through 1 year with every 16-week re-treatments, a management approach that could realistically be achieved in the real world,” Wykoff said. – by Robert Linnehan

Disclosure: Wykoff reports he is a consultant for Alimera Sciences, Allegro, Allergan, Alnylam, Apellis, Bayer, Clearside Biomedical, DORC, EyePoint, Genentech/Roche, Kodiak, Notal Vision, Novartis, ONL Therapeutics, PolyPhotonix, Recens Medical, Regeneron, Regenxbio and Santen; is a researcher for Allergan, Apellis, Clearside Biomedical, EyePoint, Genentech/Roche, Neurotech, Novartis, Opthea, Regeneron, Regenxbio, Samsung and Santen; and is a speaker for Regeneron.

    See more from Angiogenesis, Exudation and Degeneration Meeting